Home / Health / Obesity Jabs Trial Begins in Manchester
Obesity Jabs Trial Begins in Manchester
8 Dec, 2025
Summary
- A five-year trial assessing weight loss jab impact has started.
- Up to 3,000 people will participate in this real-world study.
- The trial focuses on the drug Tirzepatide, marketed as Mounjaro.
A groundbreaking five-year trial has launched in Greater Manchester, focusing on the effectiveness of weight loss jabs for individuals with obesity. The study, which began with the first patients enrolling at a GP visit, will provide real-world data on the health benefits of Tirzepatide, a drug marketed as Mounjaro.
This ambitious trial plans to involve up to 3,000 participants. It is a collaborative effort between US pharmaceutical giant Eli Lilly and the government, representing a £279 million investment aimed at addressing critical public health issues such as obesity.
Led by Professor Martin Rutter of the University of Manchester, the study will closely examine how early intervention with these drugs can effectively combat obesity. The findings are expected to shed light on new strategies for public health.
